Article

A closed-loop cell therapy engineered to autonomously secrete Activin A inhibitor protects from fibrodysplasia ossificans progressiva

2026-02-13

Abstract excerpt

Engineered cell therapies present an opportunity for endogenous, site-specific production of therapeutic agents. Here we describe a closed-loop cell therapy which secretes an inhibitor of Activin A, ActR2A-Fc, upon exposure to Activin A. We demonstrate in vivo therapeutic efficacy of this approach in a mouse model of fibrodysplasia ossificans progressiva (FOP), a morbid condition in which patients develop extensiv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3bfac517-cb13-5a01-8dbc-97ffa88e6dc4
DOI: 10.64898/2026.02.11.705403

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A closed-loop cell therapy engineered to autonomously secrete Activin A inhibitor protects from fibrodysplasia ossificans progressivaDOI 10.64898/2026.02.11.705403Read

Suppression of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva Using AAV Gene DeliverySemantic proximity Read

Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery.Semantic proximity Read

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.Semantic proximity Read

The finger 2 tip loop of Activin A is required for the formation of its non-signaling complex with ACVR1 and type II Bone Morphogenetic Protein receptorsSemantic proximity Read

An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.Semantic proximity Read

Over-expression of wild-type <i>ACVR1</i> in fibrodysplasia ossificans progressiva mice rescues perinatal lethality and inhibits heterotopic ossificationSemantic proximity Read

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.Semantic proximity Read

AAV-Mediated Targeting of the Activin A-ACVR1R206H Signaling in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read

Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop.Semantic proximity Read

ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.Semantic proximity Read

Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1R206H Transcript and Inhibit Osteogenic Differentiation.Semantic proximity Read

Fibrodysplasia ossificans progressiva.Semantic proximity Read